Sciences

Gilead Sciences is a leading American biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines in areas of unmet medical need. The company is best known for its pioneering work in antiviral therapies, particularly for the treatment of HIV, hepatitis B, hepatitis C, and influenza. In recent years, Gilead has significantly expanded its portfolio into oncology and inflammation through strategic acquisitions, including the purchase of Kite Pharma and Immunomedics. Their commercial portfolio includes blockbuster treatments such as Biktarvy for HIV, Sovaldi and Harvoni for HCV, and the cell therapy Yescarta. Gilead continues to invest heavily in research and development to address complex global health challenges, including emerging viral threats like COVID-19 with the antiviral Veklury.